Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.

ABSTRACT:

Background

Fingolimod (FTY) and dimethyl fumarate (DMF) are multiple sclerosis (MS) oral therapies that became available in 2010 and 2013, respectively.

Objective

The objective of this article is to compare discontinuation rates, efficacy, and adverse events (AEs) of FTY and DMF over two years.

Methods

Patients prescribed FTY or DMF at the Rocky Mountain MS Center at University of Colorado prior to October 2013 were identified. Clinician-reported data were retrospectively collected. Primary outcome was discontinuation of drug by the end of year two. Reasons for discontinuation were evaluated.

Results

A total of 271 FTY and 342 DMF patients were evaluated. Patients had a mean age of 42.5 (FTY) and 45.8 (DMF) years and were predominantly female (72.0% FTY; 69.6%

SUBMITTER: Vollmer B 

PROVIDER: S-EPMC5564884 | biostudies-literature | 2017 Jul-Sep

REPOSITORIES: biostudies-literature